Home › Burkitt Lymphoma › Massachusetts
Burkitt Lymphoma clinical trials in Massachusetts
8 studies for Burkitt Lymphoma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
RecruitingPhase 2
365 Days · All sexes · Updated Oct 27, 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 27, 2026 · NCT06124157Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- and 1 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT03595917The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Floating Hospital for Children at Tufts Medical Center, Boston
- Dana Faber Cancer Institute/ Boston Children's Hospital, Boston
RecruitingPhase 2
Ages 1 to 25 · All sexes · Updated May 4, 2025 · NCT03509961From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.